PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD).
According to Seaport, the results demonstrated that GlyphAgo exceeded its program target of a 2-fold increase in bioavailability compared to unmodified agomelatine, achieving therapeutic levels of agomelatine at substantially lower doses that reduce liver exposure and are projected to reduce or eliminate the need for liver function testing.
In a statement, Daphne Zohar, co-founder and CEO of Seaport, commented, “These topline data, from a well-powered Phase 1 trial, strengthen our conviction in GlyphAgo’s potential and provide further clinical validation for the Glyph platform. Based on these data, we plan to advance GlyphAgo into two parallel trials, a Phase 2a proof-of-pharmacology trial to evaluate the potential sleep benefit of GlyphAgo in patients with GAD, and a Phase 2b trial in GAD, that is a randomized placebo-controlled trial designed to be registration-enabling. We believe that GlyphAgo has the potential to bring patients with generalized anxiety disorder what could be the first new therapy in decades in the U.S. for this underserved and debilitating disorder.”
